Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
DLM Biotech (Wuhan) Co., Ltd., also known as Duolaimi Biotechnology, is a specialized biotechnology company headquartered in Wuhan, China, that focuses on the isolation, characterization, and analysis of extracellular vesicles (EVs) and exosomes. The company offers a range of proprietary products, including exosome extraction and RNA isolation kits, as well as comprehensive analytical services such as small RNA sequencing, proteomics, and lipidomics. DLM Biotech serves as a key technical partner for academic and clinical researchers, providing tools and expertise for biomarker discovery, liquid biopsy development, and the study of EV-mediated biological functions. Their products and services are widely cited in scientific literature for their role in advancing exosome-based research and diagnostics.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on DLMBiotech.